<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559115</url>
  </required_header>
  <id_info>
    <org_study_id>14-146</org_study_id>
    <nct_id>NCT02559115</nct_id>
  </id_info>
  <brief_title>68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer</brief_title>
  <official_title>A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can
      show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled
      DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study
      is being done because there are unmet medical needs to improve the current ways of detecting
      prostate cancers before surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>localizing tumors</measure>
    <time_frame>within two weeks prior to the planned prostatectomy</time_frame>
    <description>Localization will be defined using a total of 12 regions within the prostate: right and left base, midgland and apex in both peripheral and transition zones. The uptake on each region will be assessed by a radiologist blinded to standard of care imaging and clinical characteristics. Histopathological confirmation will be used as the gold standard.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PET/CT imaging with 68Ga-RM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass &lt;= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-RM2 (RM2)</intervention_name>
    <arm_group_label>PET/CT imaging with 68Ga-RM2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT Scan</intervention_name>
    <arm_group_label>PET/CT imaging with 68Ga-RM2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Biopsy proven adenocarcinoma of the prostate

          -  Patients with low-risk, intermediate-risk and high-risk tumors according to NCCN
             guidelines (2.2014) will be included

          -  Planned radical prostatectomy at MSKCC

          -  Multiparametric MRI of the pelvis (performed or planned) as routine care

        Exclusion Criteria:

          -  Patients meeting any of the following exclusion criteria will not be eligible for
             study entry:

          -  Hematologic

               -  Platelets &lt;75K/mcL

               -  ANC &lt;1.0 K/mcL

          -  Hepatic laboratory values

               -  Bilirubin &gt;2.0 x ULN (institutional upper limits of normal)

               -  AST/ALT &gt;2.5 x ULN

          -  Renal laboratory values

             o Creatinine &gt; 2.0 x ULN

          -  Claustrophobia interfering with MRI and PET/CT imaging

          -  Prior pelvic radiation

          -  Prior androgen deprivation therapy

          -  Patients deemed not surgical candidates due to prohibitive co-morbidities
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Weber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang Weber, MD, PhD</last_name>
    <phone>212-639-7373</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karim Touijer, MD</last_name>
    <phone>646-422-4486</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Weber, MD, PhD</last_name>
      <phone>212-639-7373</phone>
    </contact>
    <contact_backup>
      <last_name>Karim Touijer, MD</last_name>
      <phone>646-422-4486</phone>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Weber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>68Ga-RM2</keyword>
  <keyword>PET/CT scan</keyword>
  <keyword>Gastrin Releasing Peptide Receptor (GRPr)</keyword>
  <keyword>14-146</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrins</mesh_term>
    <mesh_term>Gastrin-Releasing Peptide</mesh_term>
    <mesh_term>Bombesin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

